Injectables – BiotechReality – Information Intelligence System for Biopharma

At the International AIDS Society (IAS) 2025 conference, Gilead Sciences showcased new results from its Phase 3 PURPOSE trials, emphasizing the effectiveness and safety of its twice-yearly injectable HIV prevention drug, lenacapavir, which is sold under the brand name Yeztugo®. The results, which span a variety of demographics, represent a major advancement in the worldwide fight against the HIV pandemic. Yeztugo® is effective and well-tolerated in a variety of demographics, including teenagers, young people, and pregnant and lactating mothers, according to the new research. This new information is especially important because these communities have previously been underrepresented in HIV prevention trials. To increase the potential reach of this cutting-edge treatment, the study also offers dosage guidelines for people taking other drugs, such as those for tuberculosis. Read More: Gilead Provides Clinical Update on Investigational HIV-1 Treatments GS-1720 and GS-4182 The presentation's main conclusion is that trial participants strongly preferred the twice-yearly injection to the daily oral medication. More than 75% of respondents said they preferred the injectable option because they felt more certain about their HIV protection and were less likely to forget a dosage. The potential for Yeztugo® to enhance pre-exposure prophylaxis (PrEP) adherence and fill important gaps in existing HIV prevention regimens is highlighted by this feedback. It’s a thrill to be back in Kigali with so many of the community, advocacy and research partners who helped make PURPOSE the most intentionally inclusive HIV prevention trial program ever conducted, As the first and only twice-yearly PrEP option, Yeztugo continues to demonstrate efficacy and tolerability among diverse populations, and we’re excited to highlight new data on this breakthrough HIV prevention option here at IAS 2025. Moupali Das Read More: Gliead Releases the Results of Phase 3 ASCENT-04/KEYNOTE-D19 Trials Shows Positive Effect for Combinational Use of Trodelvy® Plus Keytruda® In a historic step to expand access worldwide, Gilead has teamed up with The Global Fund to offer lenacapavir to up to two million individuals in low- and lower-middle-income nations at no cost. Gilead's primary objective of eradicating the HIV epidemic for all people worldwide is in line with this commitment. The new information at IAS 2025 highlights Yeztugo®'s potential to be a key component of this international initiative, providing a practical and efficient HIV prevention solution to a wide range of people. Information: Gilead Sciences Last Modified:

Tag: Injectables

Gilead Unveils Promising New Data on Twice-Yearly HIV Prevention Drug Lenacapavir

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment